IL6 and ovarian carcinoma: Among a cohort of 150 patients with newly diagnosed epithelial ovarian cancer, plasma levels of IL-6 and thrombopoietin corelated with platelet counts and in a smaller cohort, blockage of IL-6 with the humanized anti-IL-6 antibody siltuximab resulted in sustained and significant reductions of platelet counts [25].